Systematic profiling of AGO2-associated circRNAs and functional investigation reveal circN4BP2L2 as a survival-promoting regulator in T-ALL.
Researchers identified a circular RNA that promotes survival in aggressive childhood leukemia, revealing a new molecular target for future treatment development.
Using AGO2 immunoprecipitation and RNA sequencing in T-ALL cell lines, the authors built a systematic resource of AGO2-associated circRNAs and identified circN4BP2L2 as the top survival-promoting miRNA sponge whose knockdown promotes apoptosis and inhibits proliferation. The functional relevance of circN4BP2L2 was validated in primary T-ALL patient data, where high circN4BP2L2 expression correlated with a distinct gene expression phenotype—establishing a new therapeutic RNA target in this aggressive leukemia.
What the study was
- Study design
- mechanistic_in_vitro_with_patient_validation
- Population
- T-ALL cell lines (JURKAT, CCRF-CEM, MOLT-4, ALL-SIL) plus primary T-ALL patient expression data
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- Leukemia
Why it surfaced
First systematic AGO2-circRNA interactome in T-ALL (Leukemia), identifying and functionally validating circN4BP2L2 as an oncogenic miRNA sponge—adds a new regulatory layer to T-ALL biology and presents circN4BP2L2 as a potential therapeutic target in a disease with limited options for relapsed/refractory patients.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.